OptimizeRx (NASDAQ:OPRX) to Repurchase $10.00 million in Outstanding Stock

OptimizeRx (NASDAQ:OPRX) announced that its Board of Directors has approved a share buyback program on Thursday, March 5th, RTT News reports. The company plans to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

OptimizeRx Stock Performance

Shares of OPRX traded down $0.34 during trading hours on Thursday, hitting $7.53. The company had a trading volume of 949,743 shares, compared to its average volume of 404,031. The business has a fifty day moving average of $10.63 and a 200-day moving average of $14.80. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The firm has a market cap of $140.36 million, a price-to-earnings ratio of 19.67 and a beta of 1.20. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. Equities analysts anticipate that OptimizeRx will post -0.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OPRX has been the subject of a number of analyst reports. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. Citizens Jmp lifted their target price on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Finally, Stephens decreased their price target on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $20.50.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.